Indaptus Therapeutics (INDP)

• Market cap: $3.55M
• 1 day: -3.79%
• 5 days: -17.14%
• 1 month: -1.93%
• 3 months: -26.98%
• 6 months: -73.15%
• Year to date: -91.52%
• 1 year: -91.85%
• 5 years: -99.56%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Employees: 7